Form D · Pharmaceuticals
Black Swan Pharmaceuticals, Inc.
Wake Forest, NC · CIK 0001808761
Offering snapshot reported Sep 29, 2021 · SEC filing
- Reported sold
- $1.92M Offering amount: $3M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 14, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 29, 2021 | Initial | $1,916,618 | No comparison | 5 | SEC filing |
| Apr 9, 2020 | Initial | $130,240 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-415024
Simple Agreement for Future Equity
Source: Form D, filed Sep 29, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony Akkari | Director |
| Julian Arbuckle | Director |
| Steve Arnott | Director |
| Om Dhingra | Director |
| Craig Metz | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
9008 Laura Lake Drive
Wake Forest, NC, 27587
Wake Forest, NC, 27587